Interleukin (IL)-4 plays a central role in the regulation of immune homeostasis and in various immune-mediated diseases including but not limited to asthma, allergies, tuberculosis, and autoimmunity-associated interstitial lung disease (scleroderma, rheumatoid arthritis, poly- and dermatomyositis). We recently described a splice variant of IL-4, so-called IL-442. The biology of IL-442 appears to be very different from that of IL-4, however the functions of this variant are still poorly understood. We found that the expression levels of IL-442 are dramatically increased in various diseases, including in asthma, to levels that are similar to or exceed those of IL-4. Furthermore, we recently found that IL-442 changes expression levels of numerous genes in human T cells, and that the IL-442-induced changes in the expression profile differ from those induced by IL-4. Unlike IL- 4, IL-442 does not stimulate phosphorylation of STAT6 in a broad range of tested concentrations. Similar to IL- 4, IL-442 stimulates phosphorylation of Jak1, Jak3, and Tyk2 in T cells in a time- and dose-dependent fashion. Gene delivery of IL-442 to mouse lungs causes proinflammatory changes in pulmonary milieu, with the induced levels of TNF-1, IL-11, IFN-3, IL-12p40, and MCP-1 significantly exceeding those induced by gene delivery of IL-4. In bronchoalveolar lavage and blood T cells of patients with asthma, relative expression levels of IL-442 were in many cases higher than those of IL-4. We also discovered that IL-442 potently stimulates production of MCP-1 in human T cells and even more potently (by several hundred fold) upregulates IL-442 production in autocrine fashion. Based on our preliminary data, the Specific Hypothesis of this study is that IL-442 binds to a specific cell surface receptor on T cells;activates characteristic intracellular signaling that is different from signaling induced by IL-4;changes gene expression in a fashion different from that induced by IL-4, particularly stimulating its own production in autocrine fashion;and ultimately stimulates production of numerous proinflammatory and Th1 molecules. Furthermore, the hypothesis is that IL-442 causes significant proinflammatory changes in the lungs in vivo, and is associated with more severe asthma in human patients.
In Specific Aim 1, the effects of IL-442 on primary human lymphocytes, as well the regulation of its production at the molecular level, will be investigated in cell culture.
In Specific Aim 2, effects of IL-442 gene delivery in vivo will be investigated in normal mice as well as in an ovalbumin-sensitized mouse model of asthma.
In Specific Aim 3, the association of IL-442 with disease severity in asthma patients will be studied. This study is directly relevant to Veterans Healthcare. Many of the IL-4-mediated diseases have no known cures and are widely spread in the general population and particularly in veterans. These diseases are chronic, severe, debilitating, and even deadly. The strengths of this investigation are that it addresses a novel topic in a mechanistic way;that it combines mechanistic studies in cell culture, in experimental animals, and in human patients;and that it deals with a molecule that is involved in the mechanisms of numerous diseases that are prevalent in veterans. This study is expected to generate a wealth of novel information on IL-442 as a potential diagnostic marker as well as important target for future therapeutic modulation of numerous diseases in veterans.
Production of a body molecule called interleukin-4 (IL-4) can be elevated and drive disease processes in the lungs, liver, skin, and other organs. All of these IL-4-dependent chronic diseases may develop with aging or as a consequence of military exposures, thus making them prevalent in the veteran population. We recently discovered that IL-4 is made in two forms, traditional IL-4 and a form called IL-4-delta-2 (IL-442). We discovered that this other form is excessively produced in patients and acts differently from the traditional IL-4 on the cells of the body. The proposed research will look at the effects of IL-442 on the cells isolated from humans, investigate the disease caused by excess IL-442 in mouse lungs, and determine how excess IL-442 in humans is associated with disease severity. The results will form the basis for development of new therapies that target IL-442 in patients, particularly in veterans, with the goal of attenuating or curing diseases in veterans, and thus improving veterans'health.
| Kopach, Pavel; Lockatell, Virginia; Pickering, Edward M et al. (2014) IFN-? directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism. J Biol Chem 289:11829-43 |
| Luzina, Irina G; Kopach, Pavel; Lockatell, Virginia et al. (2013) Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol 49:999-1008 |
| Todd, Nevins W; Scheraga, Rachel G; Galvin, Jeffrey R et al. (2013) Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis. J Inflamm Res 6:63-70 |
| Luzina, Irina G; Pickering, Edward M; Kopach, Pavel et al. (2012) Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol 189:403-10 |
| Luzina, Irina G; Keegan, Achsah D; Heller, Nicola M et al. (2012) Regulation of inflammation by interleukin-4: a review of ""alternatives"". J Leukoc Biol 92:753-64 |
